Appendix 1 to the guideline on the evaluation of anticancer medicinal products in man - methodological consideration for using progression-free survival (PFS) or disease-free survival (DFS) in confirmatory trials
| Current effective version |
|
| Reference number | CHMP/27994/2008 Rev. 1 |
| Published | 11/01/2013 |
| Effective from | 01/07/2013 |
| Keywords | Cancer, malignancy, biomarker, targeted drugs, pharmacogenomics |
| Description | This document is an appendix to the guideline on the evaluation of anticancer medicinal products in man. It provides a guidance on the use of progression-free survival or disease-free survival as endpoint in clinical efficacy trials. |
Document history
Revision 1 Current version | In operation: 01/07/2013–present Published: 22/12/2011 | |
| First version | In operation: 01/08/2008–30/06/2013 Published: 27/07/2006 |